RB1 and liposarcoma: In a phase I trial with palbociclib (PD 0332991), Schwartz et al. treated 33 patients with Rb-positive solid tumors or refractory non-Hodgkin’s lymphoma and found durable SD in 4 out of 7 patients with liposarcoma, subtype unspecified [47].